Trulicity is Eli Lilly and company's once-weekly, injectable
glucagon-like peptide-1 receptor agonist approved to improve blood sugar in adults with type 2 diabetes.
A new once-weekly analogue of human
glucagon-like peptide-1 (GLP-1), Ozempic, is indicated as monotherapy when metformin is considered inappropriate because of intolerance or is contraindicated, and as an addition to other medicinal products to treat diabetes.
Unlike other
glucagon-like peptide-1 (GLP-1) receptor agonists, Bydureon BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the active ingredient, exenatide, to help patients reach and maintain steady state.
This patent, which has been awarded by the Canadian Intellectual Property Office, covers the company's invention of an oral
glucagon-like peptide-1 (GLP-1) analog.
This includes new medication classes as add-on therapy to metformin such as the dipeptidyl peptidase-4 inhibitors and
glucagon-like peptide-1 receptor agonists that act on the incretin system, and the sodium glucose cotransporter-2 inhibitors that act on the kidney.
6 enters a new class of diabetes treatments that combine a basal insulin and a
glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single, once-daily injection.
Based on the drug therapy the pen needles market is segmented into insulin,
glucagon-like peptide-1 and growth hormones.
Discovery of the Once-Weekly
Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Patients taking dipeptidyl peptidase-4 (DPP-4) inhibitors and
glucagon-like peptide-1 (GLP-1) analogues were compared with those taking non-incretin-based drugs.
A tumour that secretes
glucagon-like peptide-1 and somatostatin
There are two predominant incretins:
Glucagon-like peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Peptide (GIP) (Also known as gastric inhibitory peptide).
Stimulation of
glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line.
